US long-acting opioid REMS at least a year away
This article was originally published in Scrip
Executive Summary
A recent US FDA regulatory action suggests implementation of a single risk evaluation and mitigation strategy (REMS) for the class of long-acting opioids and immediate-release methadone is well over a year away.